Senesco Technologies (SVON) and Soligenix (SNGX) Head-To-Head Survey
Senesco Technologies (OTCMKTS: SVON) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.
Risk and Volatility
Senesco Technologies has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500.
Insider and Institutional Ownership
2.0% of Soligenix shares are owned by institutional investors. 25.1% of Senesco Technologies shares are owned by company insiders. Comparatively, 5.0% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Senesco Technologies and Soligenix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations for Senesco Technologies and Soligenix, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Soligenix has a consensus price target of $8.00, indicating a potential upside of 258.74%. Given Soligenix’s higher probable upside, analysts clearly believe Soligenix is more favorable than Senesco Technologies.
Valuation and Earnings
This table compares Senesco Technologies and Soligenix’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Senesco Technologies||N/A||N/A||-$2.26 million||($0.24)||-1.18|
|Soligenix||$6.98 million||1.83||-$6.76 million||($1.36)||-1.64|
Senesco Technologies has higher revenue, but lower earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Senesco Technologies, indicating that it is currently the more affordable of the two stocks.
Senesco Technologies beats Soligenix on 6 of the 11 factors compared between the two stocks.
Senesco Technologies Company Profile
Sevion Therapeutics, Inc. is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company’s antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.
Soligenix Company Profile
Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.
Receive News & Stock Ratings for Senesco Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senesco Technologies Inc. and related stocks with our FREE daily email newsletter.